(Feb 3): Singapore’s battered property firms are hitting a snag in their recovery after rising coronavirus infections led to an extension of remote work in the city-state.
Shares of commercial developers and real estate investment trusts have fallen since authorities announced last month that working from home will remain the default arrangement. The government is trying to minimize the risk of transmission at offices after some cases in the workplace led to community clusters.
The move adds to headwinds for developers and REITs, amid questions over what the future holds for offices worldwide even after the pandemic. It will be harder to lease out vacancies and there will be pressure to lower rents if the work-from-home arrangement persists, said Terence Chua, an analyst at Phillip Securities Research Pte.
SINGAPORE'S benchmark Straits Times Index ended at 2,863.01 on Wednesday, just 3.33 points or 0.12 per cent higher than the day before, in response to the Georgia Senate run-offs and oil price jump. Read more at The Business Times.
Singapore's benchmark Straits Times Index ended at 2,863.01 yesterday, just 3.33 points or 0.12 per cent higher than the day before, in its response to the run-off elections for two seats in the United States Senate in the state of Georgia and the jump in oil prices.. Read more at straitstimes.com.
STI nearly flat; SembMarine jumps as oil prices cross US$50 businesstimes.com.sg - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstimes.com.sg Daily Mail and Mail on Sunday newspapers.
Bayer, National Heart Center Singapore to develop explorative cardiovascular center
By Anh Nguyen December 22, 2020 | 04:43 pm GMT+7
Bayer and National Heart Center Singapore (NHCS) announced they had inked a five-year agreement to develop a “Center of Excellence for Explorative Cardiovascular Studies.”
The center aims to boost patient-centricity in research and development (R&D) and improve treatment outcomes in cardiovascular disease (CVD) management.
Combining NHCS’s vast experience in managing Asian CVD patients and clinical research with Bayer’s expertise in pharmaceutical R&D, the center will generate and integrate high quality patient data into early clinical research that would allow better understanding of the underlying biology of CVDs. Results could potentially lead to future targeted therapies to address unmet medical needs in defined patient populations. Bayer will contribute S$5.4 million ($4 million) towards the setup of the center.